Trial Outcomes & Findings for Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice (NCT NCT04517669)

Last Updated: 2025-10-14

Results Overview

PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global psoriatic arthritis assessment (PAA), physician global PAA, each scored on 100 mm visual analog scale (VAS), 0=no disease activity (DA), 100=maximum DA; tender joint count (TJC) (0-68); swollen joint count (SJC) (0-66); Leed's Enthesitis index (LEI) score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; physical component summary (PCS) of short form 36 (SF-36) score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease. LDA was defined as PASDAS score less than or equal to (\<=) 3.2.

Recruitment status

COMPLETED

Target enrollment

116 participants

Primary outcome timeframe

At Month 6

Results posted on

2025-10-14

Participant Flow

Participants diagnosed with psoriatic arthritis (PsA) and treated with tofacitinib in routine clinical practice were included in this prospective study.

A total of 116 participants from rheumatologists and/or PsA specialist centres across 8 countries (Belgium, Denmark, Finland, France, Israel, Netherlands, Spain, and Sweden) signed the informed consent.

Participant milestones

Participant milestones
Measure	All Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Overall Study STARTED	116
Overall Study Safety (Started Tofacitinib Irrespective of Eligibility Criteria)	113
Overall Study Full Analysis Set	109
Overall Study COMPLETED	59
Overall Study NOT COMPLETED	57

Reasons for withdrawal

Reasons for withdrawal
Measure	All Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Overall Study Lost to Follow-up	2
Overall Study Withdrawal by Subject	3
Overall Study Drug withdrawn	44
Overall Study Other	1
Overall Study Eligibility criteria not met	4
Overall Study Did not receive treatment	3

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	All Participants n=113 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Age, Continuous	49.8 Years STANDARD_DEVIATION 10.47 • n=113 Participants
Sex: Female, Male Female	63 Participants n=113 Participants
Sex: Female, Male Male	50 Participants n=113 Participants

PRIMARY outcome

Timeframe: At Month 6

Population: Full analysis set (FAS) included all enrolled participants who received at least one dose (including partial dose) of study medication. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows.

Outcome measures

Outcome measures
Measure	All Participants n=72 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 Overall	43.1 Percentage of participants Interval 29.9 to 56.3
Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 Tofacitinib monotherapy	46.9 Percentage of participants Interval 31.4 to 62.4
Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 Combined tofacitinib and methotrexate (MTX) therapy	33.4 Percentage of participants Interval 9.4 to 57.5
Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 Combined tofacitinib and other conventional synthetic disease-modifying antirheumatic drug (csDMARD)	4.0 Percentage of participants Upper limit and lower limit of 95% confidence interval (CI) could not be calculated due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: At Month 3 and Month 12

PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease. LDA was defined as PASDAS score less than or equal to (\<=) 3.2.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Overall-Month 3	23.5 Percentage of participants Interval 13.9 to 36.9
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Tofacitinib monotherapy-Month 3	21.1 Percentage of participants Interval 10.8 to 36.6
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Combined tofacitinib and MTX therapy-Month 3	33.3 Percentage of participants Interval 13.6 to 61.2
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Combined tofacitinib and other csDMARD-Month 3	0 Percentage of participants Interval 0.0 to 82.9
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Overall-Month 12	46.2 Percentage of participants Interval 28.7 to 64.5
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Tofacitinib monotherapy-Month 12	47.4 Percentage of participants Interval 27.3 to 68.3
Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12 Combined tofacitinib and MTX therapy-Month 12	42.9 Percentage of participants Interval 15.8 to 75.0

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

A participant was classified as MDA achieved if they met 5 of 7 criteria: (i) (TJC66) \<=1, (ii) (SJC68)\<=1, (iii) psoriasis area and severity index (PASI) score \<=1 (PASI=combined assessment of lesion severity and area affected into single score; range=0 \[no disease\] to 72 \[maximal disease\], higher scores=more disease. or body surface area (BSA) \<=3%,(iv) patient pain assessment (VAS, 0-100) \<=15; where 0='no pain' and 100='pain as severe as can be imagined', higher scores=more pain, (v) patient global assessment (VAS, 0-100) \<=20, where 0='lowest level of disease activity' and 100= 'highest level of disease activity, higher scores=more disease activity, (vi) health assessment questionnaire-disability index (HAQ- DI) \<=0.5; scale ranged=0-3, where 0='normal or no difficulty' and 3='inability to perform', higher scores=more difficulty, (vii) tender enthesial points \<=1 using Leed's index range=0=non tender to 6=more enthesitis burden, higher scores=more burden.

Outcome measures

Outcome measures
Measure	All Participants n=91 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Overall-Month 3	17.6 Percentage of participants Interval 11.0 to 26.8
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	16.7 Percentage of participants Interval 9.4 to 27.6
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	21.7 Percentage of participants Interval 9.2 to 42.3
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	0 Percentage of participants Interval 0.0 to 71.1
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Overall-Month 6	42.3 Percentage of participants Interval 31.4 to 53.9
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	42.0 Percentage of participants Interval 29.4 to 55.8
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	45.0 Percentage of participants Interval 25.8 to 65.8
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 6	0 Percentage of participants Interval 0.0 to 82.9
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Overall-Month 12	43.9 Percentage of participants Interval 31.8 to 56.7
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	45.0 Percentage of participants Interval 30.7 to 60.2
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	43.8 Percentage of participants Interval 23.1 to 66.8
Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 12	0 Percentage of participants Interval 0.0 to 82.9

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease. Remission was defined as PASDAS score less than or equal to (\<=) 1.9.

Outcome measures

Outcome measures
Measure	All Participants n=66 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Overall-Month 3	12.1 Percentage of participants Interval 6.0 to 22.4
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	14.3 Percentage of participants Interval 6.8 to 27.0
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	7.1 Percentage of participants Interval 0.0 to 33.5
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	0 Percentage of participants Interval 0.0 to 62.0
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Overall-Month 6	15.7 Percentage of participants Interval 7.9 to 28.3
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	20.0 Percentage of participants Interval 9.7 to 36.2
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	6.7 Percentage of participants Interval 0.0 to 31.8
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 6	0 Percentage of participants Interval 0.0 to 82.9
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Overall-Month 12	21.6 Percentage of participants Interval 11.1 to 37.4
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	25.9 Percentage of participants Interval 12.9 to 44.9
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	11.1 Percentage of participants Interval 0.0 to 45.7
Percentage of Participants Who Achieved Remission Based on PASDAS at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 12	0 Percentage of participants Interval 0.0 to 82.9

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

DAPSA was composite disease activity measure and was calculated as: SJC66 + TJC68 + patient global assessment VAS (0 to 10 cm VAS, 0= excellent and 10= poor, higher scores indicated more disease activity) + patient pain assessment (0 to 10 cm VAS, 0= no pain, 10= worst possible pain, higher scores indicated more pain) + CRP (mg/dL). DAPSA score ranged from 0 to 164, higher scores indicated more disease activity. Remission was defined as DAPSA score =\<4.0.

Outcome measures

Outcome measures
Measure	All Participants n=53 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Overall-Month 3	11.3 Percentage of participants Interval 4.9 to 22.9
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	11.6 Percentage of participants Interval 4.6 to 24.9
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	11.1 Percentage of participants Interval 0.0 to 45.7
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	0 Percentage of participants Interval 0.0 to 82.9
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Overall-Month 6	28.9 Percentage of participants Interval 17.6 to 43.5
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	36.4 Percentage of participants Interval 22.1 to 53.4
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	8.3 Percentage of participants Interval 0.0 to 37.5
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Overall-Month 12	38.7 Percentage of participants Interval 23.7 to 56.2
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	47.6 Percentage of participants Interval 28.3 to 67.6
Percentage of Participants Who Achieved Remission Based on Disease Activity in Psoriatic Arthritis (DAPSA) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	20.0 Percentage of participants Interval 4.6 to 52.1

SECONDARY outcome

Timeframe: Baseline (measurement at enrollment), at Month 3, Month 6 and Month 12

PsAID12: questionnaire used for evaluating how much PsA impacted quality of life (QoL) and comprised of following domains: Pain, Fatigue, Skin problems, Work and/or leisure activities, Function, Discomfort, Sleep disturbance, Coping, Anxiety, Embarrassment, Social life and Depression. Each one of domain was based on a 0-10 numerical rating scale (NRS) and with different weight. PsAID12= (PsAID12.Q1 \[pain\] NRS value\*3) +(PsAID12.Q2\[fatigue\] NRS value\*2) +(PsAID12.Q3 \[skin\] NRS value\*2) +(PsAID12.Q4\[Work and/or leisure activities\] NRS value\*2) +(PsAID12.Q5\[function\] NRS value\*2) +(PsAID12.Q6\[discomfort\]NRS value\*2) +(PsAID12.Q7\[sleep\] NRS value\*2) +(PsAID12.Q8 \[coping\]NRS value\*1) +(PsAID12.Q9\[anxiety\] NRS value\*1) +(PsAID12.Q10\[embarrassment\] NRS value\*1) +(PsAID12.Q11\[social life\] NRS value\*1) +(PsAID12.Q12\[depression\] NRS value\*1). Total is divided by 20 for final score. Range of final PsAID score is 0-10 (higher numbers indicate worse status).

Outcome measures

Outcome measures
Measure	All Participants n=89 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	-0.9 Units on a scale Interval -1.91 to 0.08
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 6	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Overall-Month 12	-1.1 Units on a scale Interval -1.61 to -0.56
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	-1.3 Units on a scale Interval -1.94 to -0.64
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	-0.7 Units on a scale Interval -1.69 to 0.25
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 12	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Overall-Month 3	-1.3 Units on a scale Interval -1.69 to -0.84
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	-1.4 Units on a scale Interval -1.91 to -0.86
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	-1.0 Units on a scale Interval -1.84 to -0.15
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Overall-Month 6	-1.3 Units on a scale Interval -1.79 to -0.8
Change From Baseline in Psoriatic Arthritis Impact of Disease 12 Questions (PsAID12) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	-1.5 Units on a scale Interval -2.06 to -0.87

SECONDARY outcome

Timeframe: Baseline (measurement at enrollment), at Month 3, Month 6 and Month 12

The SPARCC-EI evaluated 16 enthesial sites: greater trochanter (Right/Left \[R/L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial epicondyles (R/L), lateral epicondyles (R/L) and supraspinatus insertion (R/L) for the presence or absence of tenderness. Tenderness at each site was quantified as: 0 = non-tender and 1 = tender. The maximum score of the SPARCC-EI was 16. SPARCC-EI score range: 0 (no enthesitis) to 16 (enthesitis is present at all assessed sites), higher scores indicated more presence of enthesitis.

Outcome measures

Outcome measures
Measure	All Participants n=57 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Overall-Month 3	0.1 Units on a scale Interval -0.67 to 0.85
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	0.1 Units on a scale Interval -0.8 to 0.95
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	0.2 Units on a scale Interval -1.87 to 2.18
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Overall-Month 6	-0.8 Units on a scale Interval -1.47 to -0.21
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	-0.4 Units on a scale Interval -1.17 to 0.28
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	-1.8 Units on a scale Interval -3.2 to -0.39
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Overall-Month 12	-0.3 Units on a scale Interval -0.95 to 0.44
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	0.0 Units on a scale Interval -0.81 to 0.82
Change From Baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC-EI) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	-0.9 Units on a scale Interval -2.42 to 0.71

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Population: The FAS included all enrolled participants who received at least one dose (including partial dose) of study medication. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows. All participants in "Overall Number of Participants Analyzed" contributed data to the table but may not have data evaluable for every row.

BMI = Weight (kilograms \[kg\]) / Height (meter square \[m\]\^2). LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease. In this outcome measure, participants with PASDAS scores are reported according to BMI categories of 18.5 - \<25 kg/m\^2, 25 - \<30 kg/m\^2, \>= 30 kg/m\^2 and missing.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 18.5 - <25 kg/m^2-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 25 - <30 kg/m^2-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: >= 30 kg/m^2-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: Missing-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 18.5 - <25 kg/m^2-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 25 - <30 kg/m^2-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: >= 30 kg/m^2-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: Missing-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 18.5 - <25 kg/m^2-Month 12	5 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: 25 - <30 kg/m^2-Month 12	4 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: >= 30 kg/m^2-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Overall: Missing-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 18.5 - <25 kg/m^2-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 25 - <30 kg/m^2-Month 3	5 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: >= 30 kg/m^2-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 18.5 - <25 kg/m^2-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 25 - <30 kg/m^2-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: >= 30 kg/m^2-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 18.5 - <25 kg/m^2-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: 25 - <30 kg/m^2-Month 12	4 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: >= 30 kg/m^2-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: 18.5 - <25 kg/m^2-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: 25 - <30 kg/m^2-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 30 kg/m^2-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: 18.5 - <25 kg/m^2-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: 25 - <30 kg/m^2-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 30 kg/m^2-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: 18.5 - <25 kg/m^2-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 30 kg/m^2-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Body Mass Index (BMI) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: >= 30 kg/m^2-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Participants who achieved LDA according to treatment line were reported in this outcome measure. Treatment line included: tofacitinib monotherapy, combination therapy with MTX, and combination therapy with other csDMARDs. LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Tofacitinib as monotherapy-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Combination therapy with MTX-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Combination with other csDMARD-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Tofacitinib as monotherapy-Month 6	15 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Combination therapy with MTX-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Tofacitinib as monotherapy-Month 12	9 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Overall: Combination therapy with MTX-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Tofacitinib monotherapy: Tofacitinib as monotherapy-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Tofacitinib monotherapy: Tofacitinib as monotherapy-Month 6	15 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Tofacitinib monotherapy: Tofacitinib as monotherapy-Month 12	9 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Combination therapy with MTX-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Combination therapy with MTX-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Combination therapy with MTX-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Treatment Line at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Combination with other csDMARD-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Duration of current episode of symptoms prior to enrollment were presented as: \< 6, \>=6 weeks. LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: < 6 weeks-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: >= 6 weeks-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: Missing-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: < 6 weeks-Month 6	11 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: >= 6 weeks-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: Missing-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: < 6 weeks-Month 12	4 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Overall: >= 6 weeks-Month 12	8 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: < 6 weeks-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: >= 6 weeks-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: < 6 weeks-Month 6	7 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: >= 6 weeks-Month 6	7 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: < 6 weeks-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Tofacitinib monotherapy: >= 6 weeks-Month 12	7 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: < 6 weeks-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 6 weeks-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: < 6 weeks-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 6 weeks-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: < 6 weeks-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: >= 6 weeks-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Duration of Current Episode Symptoms of at Least 6 Weeks Prior to Enrollment at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: >= 6 weeks-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

ESR result=abnormal if test result was above normal range. ESR normal range:0-50 years(male \<15 mm/h, female \<20 mm/h), 51-85 years(\<20 mm/h males and \<30 mm/h females),older than 85 years(\<30 mm/h males and \<42 mm/h females). Number of participants who achieved LDA according to ESR results(normal and abnormal) were reported. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of following:participant global PAA,physician global PAA,each scored on 100 mm VAS,0=no DA, 100=maximum DA; TJC(0-68); SJC(0-66); LEI score=0-6;0=non tender,6=more enthesitis burden; tender dactylitis digit score=0-3,0=no tenderness,3=participant withdrew digit; PCS of SF-36 score=0-100; 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged=0(no disease)to 10(severe disease);higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Abnormal-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Normal-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Missing-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Abnormal-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Normal-Month 6	10 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Missing-Month 6	6 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Abnormal-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Normal-Month 12	7 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Overall: Missing-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 12	5 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Erythrocyte Sedimentation Rate (ESR) Results at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Normal-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

For CRP, result was considered abnormal if t the test result was above the normal range (0.3 to 10 mg/L). LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Abnormal-Month 3	7 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Normal-Month 3	5 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Abnormal-Month 6	8 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Normal-Month 6	12 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Abnormal-Month 12	4 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Overall: Normal-Month 12	8 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 3	4 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 3	4 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 6	5 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 6	10 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Abnormal-Month 12	2 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Tofacitinib monotherapy: Normal-Month 12	7 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 3	3 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 3	1 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 6	3 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 6	2 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Abnormal-Month 12	2 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Normal-Month 12	1 Participants
Number of Participants Who Achieved LDA According to C-reactive Protein (CRP) Results at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Normal-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Number of participants who achieved LDA according to presence (present/absent) of rheumatoid nodules is presented in this outcome measure. LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Absent-Month 3	12 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Missing-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Absent-Month 6	20 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Missing-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Absent-Month 12	12 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Overall: Missing-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 6	15 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 12	9 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Presence of Rheumatoid Nodules at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Absent-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Unequivocal radiological erosion: 'present',if Sharp-Van der Heijde modified score (S-VH MS)for erosion \>0;'absent',if S-VH MS for erosion score=0. S-VH MS sum of erosion,JSN scores(range 0-528). Higher score=more severe disease. If a component score is missing, S-VH MS is missing. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of following: participant global PAA,physician global PAA,each scored on 100 mm VAS,0=no DA,100=maximum DA; TJC(0-68); SJC(0-66); LEI score range=0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score range=0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score range=0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0(no disease)to 10(severe disease); higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Present-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Absent-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Missing-Month 3	10 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Present-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Absent-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Missing-Month 6	17 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Present-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Absent-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Overall: Missing-Month 12	11 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	7 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	12 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 12	8 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Radiological Erosion at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Missing-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Unequivocal Bony decalcification was reported as present or absent at enrollment. LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of the following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Present-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Absent-Month 3	7 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Missing-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Present-Month 6	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Absent-Month 6	12 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Missing-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Present-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Absent-Month 12	7 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Overall: Missing-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 6	11 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Present-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Absent-Month 12	6 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Tofacitinib monotherapy: Missing-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Present-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Present-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 6	3 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Present-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Absent-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Missing-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Presence of Unequivocal Bony Decalcification Localized to the Joints of the Hands and Wrists at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Absent-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Arthritis at enrollment was identified when a participant reported swelling and/or tenderness/pain in any joint. Number of participants who achieved LDA according to presence (Yes/No) of symmetric arthritis was reported. LDA was defined as PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of following: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC (0-68); SJC (0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Overall: No-Month 3	12 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Overall: Yes-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Overall: No-Month 6	20 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Overall: Yes-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Overall: No-Month 12	12 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	15 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	9 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Presence of Symmetric Arthritis at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: No-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Hand joints included metacarpal phalangeal joints(MCP), finger proximal interphalangeal and finger distal interphalangeal joints. Number of participants who achieved LDA according to presence(Yes/No) of arthritis of any of hand joints was reported. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA which incorporated assessment of following: participant global PAA,physician global PAA, each scored on 100 mm VAS,0=no DA,100=maximum DA;TJC(0-68); SJC(0-66); LEI score ranging from 0-6; where 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3 where 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; where 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores indicated more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: No-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: Yes-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: No-Month 6	6 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: Yes-Month 6	14 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: No-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Overall: Yes-Month 12	11 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	11 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 12	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 6	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of the Hand Joints at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Yes-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Medium joints=temporomandibular, sternoclavicular, acromioclavicular, finger proximal interphalangeal, finger distal interphalangeal and tarsus/midfoot(feet) joints. Large joints=glenohumeral, elbows, hips, knees and ankles joint. Number of participants who achieved LDA according to presence (Yes/No) of arthritis of only 1 medium-large joint was reported. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA incorporated assessment of: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA;TJC(0-68);SJC(0-66); LEI score ranging from 0-6;0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3;0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100;0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS score (0-10) uses a weighted formula; higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: No-Month 3	10 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: Yes-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: No-Month 6	17 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: Yes-Month 6	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: No-Month 12	11 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Overall: Yes-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	7 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	14 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	9 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 3	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 6	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 6	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of Only 1 Medium-Large Joint at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: No-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Medium joints=temporomandibular, sternoclavicular, acromioclavicular, finger proximal interphalangeal (IP), finger distal interphalangeal, tarsus/midfoot (feet). Large joints=glenohumeral, elbows, hips, knees, ankles. Small joints=MCP, proximal IP, second through fifth metatarsal phalangeal (MTP), thumb IP, wrists. Number of participants who achieved LDA according to presence (Yes/No) arthritis of 2-10 medium-large joints and/or 1-3 small joints was reported. LDA=PASDAS score =\<3.2. PASDAS is a composite PsA activity score including: participant /physician global (VAS 0-100; 0=no DA, 100=maximum DA), TJC (0-68), SJC (0-66), LEI (0-6; 0=non tender, 6=more enthesitis burden), tender dactylitis digit score (0-3; 0=no tenderness, 3=participant withdrew digit), SF-36 PCS (0-100; 0=severe physical health limitations, 100=excellent physical health),CRP in mg/L. PASDAS score (0-10) uses a weighted formula; higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: No-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: Yes-Month 3	12 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: No-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: Yes-Month 6	19 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: No-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Overall: Yes-Month 12	11 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	14 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 12	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of 2-10 Medium-Large Joints and/or 1-3 Small Joints at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Yes-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Large joints=glenohumeral, elbows, hips, knees and ankles joint. Small joints=MCP, proximal IP, second through fifth MTP, thumb IP, wrists. Number of participants who achieved LDA according to presence (Yes/No) of arthritis of 4-10 small joints with or without involvement of large joints was reported. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA incorporated assessment of: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA;TJC(0-68); SJC(0-66); LEI score range=0-6; 0=non tender, 6=more enthesitis burden; tender dactylitis digit score range=0-3; 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: No-Month 3	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: Yes-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: No-Month 6	12 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: Yes-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: No-Month 12	6 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Overall: Yes-Month 12	6 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	8 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	7 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 12	5 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 6	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 12	1 Participants
Number of Participants Who Achieved LDA According to Arthritis of 4-10 Small Joints With or Without Involvement of Large Joints at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: No-Month 3	0 Participants

SECONDARY outcome

Timeframe: At Month 3, Month 6 and Month 12

Small joints=MCP, proximal IP, second through fifth MTP, thumb IP, wrists. Number of participants who achieved LDA according to presence (Yes/No) of arthritis of \>10 joints (with at least one small joint) was reported in this outcome measure. LDA=PASDAS score =\<3.2. PASDAS=composite disease activity measure for PsA incorporated assessment of: participant global PAA, physician global PAA, each scored on 100 mm VAS, 0=no DA, 100=maximum DA; TJC(0-68); SJC(0-66); LEI score ranging from 0-6; 0=non tender, 6=more enthesitis burden; tender dactylitis digit score ranging from 0-3; 0=no tenderness, 3=participant withdrew digit; PCS of SF-36 score ranging from 0-100; 0=severe physical health limitations and 100=excellent physical health and CRP in mg/L. PASDAS total score was calculated using a weighted formula and ranged from 0 (no disease) to 10 (severe disease); higher scores=more severe disease.

Outcome measures

Outcome measures
Measure	All Participants n=51 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: No-Month 3	10 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: Yes-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: No-Month 6	16 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: Yes-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: No-Month 12	10 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Overall: Yes-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 3	6 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 3	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 6	11 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 6	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: No-Month 12	7 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Tofacitinib monotherapy: Yes-Month 12	2 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 3	4 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 3	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 6	5 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 6	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: No-Month 12	3 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Yes-Month 12	0 Participants
Number of Participants Who Achieved LDA According to Arthritis of >10 Joints (With at Least One Small Joint) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: No-Month 3	0 Participants

SECONDARY outcome

Timeframe: Baseline (measurement at enrollment), Month 3, Month 6 and Month 12

The SF-36 is a participant administered scale assessing general quality of life. It consists of self-administered 36-item questionnaire that measured 8 health domains: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. These 8 domains are also summarized as physical and mental component scores. The score for each domain and component score is the mean of the individual question scores, which are scaled from 0 (minimum) to 100 (maximum), where high scores in each dimension and high overall scores indicate a better quality of life.

Outcome measures

Outcome measures
Measure	All Participants n=87 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Mental health component summary score-Month 6	2.6 Units on a scale Interval 0.05 to 5.2
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Physical health component summary score-Month 3	3.6 Units on a scale Interval 0.67 to 6.44
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Mental health component summary score-Month 3	1.5 Units on a scale Interval -1.44 to 4.51
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Physical health component summary score-Month 6	6.2 Units on a scale Interval 3.94 to 8.51
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Physical health component summary score-Month 3	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Physical health component summary score-Month 3	4.8 Units on a scale Interval 3.0 to 6.56
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Mental health component summary score-Month 3	2.4 Units on a scale Interval 0.31 to 4.52
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Physical health component summary score-Month 3	5.0 Units on a scale Interval 2.78 to 7.2
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Mental health component summary score-Month 3	2.5 Units on a scale Interval -0.23 to 5.26
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Mental health component summary score-Month 3	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Physical health component summary score-Month 6	5.5 Units on a scale Interval 3.53 to 7.4
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Mental health component summary score-Month 6	2.9 Units on a scale Interval -0.41 to 6.2
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Physical health component summary score-Month 6	3.2 Units on a scale Interval -0.48 to 6.92
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Mental health component summary score-Month 6	0.9 Units on a scale Interval -3.22 to 5.01
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Physical health component summary score-Month 6	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Mental health component summary score-Month 6	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Physical health component summary score-Month 12	5.5 Units on a scale Interval 3.33 to 7.69
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Overall: Mental health component summary score-Month 12	3.0 Units on a scale Interval 0.11 to 5.83
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Physical health component summary score-Month 12	6.8 Units on a scale Interval 4.06 to 9.45
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Tofacitinib monotherapy: Mental health component summary score-Month 12	4.5 Units on a scale Interval 1.04 to 8.03
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Physical health component summary score-Month 12	3.8 Units on a scale Interval 0.6 to 6.97
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and MTX therapy: Mental health component summary score-Month 12	-1.8 Units on a scale Interval -6.33 to 2.74
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Physical health component summary score-Month 12	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in Quality of Life (QoL) Based on Short Form 36 (SF-36) Score at Months 3, 6 and 12 Combined tofacitinib and other csDMARD: Mental health component summary score-Month 12	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Baseline (measurement at enrollment), Month 3, Month 6 and Month 12

The HAQ-DI41 assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consisted of 2-3 items. For each question in the questionnaire, the level of difficulty was scored from 0 to 3 with 0 =no difficulty," 1 = "some difficulty," 2 = "much difficulty," and 3 = "unable to do". The disability index was computed by adding the scores for each of the components and dividing by the number of components with an available score. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

Outcome measures

Outcome measures
Measure	All Participants n=88 Participants Participants diagnosed with PsA and treated with tofacitinib in routine clinical practice were included. No study drug was administered as part of this study. Participants were followed for up to 12 months.
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Overall-Month 3	-0.1 Units on a scale Interval -0.21 to -0.01
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 3	-0.1 Units on a scale Interval -0.24 to 0.0
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 3	-0.0 Units on a scale Interval -0.23 to 0.14
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 3	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Overall-Month 6	-0.1 Units on a scale Interval -0.23 to 0.0
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 6	-0.1 Units on a scale Interval -0.29 to 0.01
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 6	0.0 Units on a scale Interval -0.2 to 0.2
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 6	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Overall-Month 12	-0.2 Units on a scale Interval -0.32 to -0.02
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Tofacitinib monotherapy-Month 12	-0.2 Units on a scale Interval -0.39 to 0.0
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and MTX therapy-Month 12	-0.2 Units on a scale Interval -0.39 to 0.07
Change From Baseline in QoL Based on Health Assessment Questionnaire - Disability Index (HAQ-DI41) at Months 3, 6 and 12 Combined tofacitinib and other csDMARD-Month 12	NA Units on a scale Least squares mean and 95% CI limits could not be calculated due to insufficient number of participants with events.

Adverse Events

All Participants

Serious events: 7 serious events

Other events: 50 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	All Participants n=113 participants at risk All participants with a diagnosis of PsA who received tofacitinib up to 12 months of follow-up were included in this retrospective observational study.
Infections and infestations Pyelonephritis	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Infections and infestations Subcutaneous abscess	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell leukaemia	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Cardiac disorders Acute myocardial infarction	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Gastrointestinal disorders Intestinal obstruction	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Musculoskeletal and connective tissue disorders Back pain	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Vascular disorders Deep vein thrombosis	0.88% 1/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.

Other adverse events

Other adverse events
Measure	All Participants n=113 participants at risk All participants with a diagnosis of PsA who received tofacitinib up to 12 months of follow-up were included in this retrospective observational study.
General disorders Drug ineffective	18.6% 21/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Infections and infestations COVID-19	8.8% 10/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Infections and infestations Influenza	2.7% 3/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Infections and infestations Nasopharyngitis	2.7% 3/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Infections and infestations Urinary tract infection	2.7% 3/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Gastrointestinal disorders Nausea	4.4% 5/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Gastrointestinal disorders Abdominal pain	3.5% 4/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Gastrointestinal disorders Abdominal pain upper	2.7% 3/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Nervous system disorders Headache	7.1% 8/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Musculoskeletal and connective tissue disorders Arthralgia	3.5% 4/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.
Skin and subcutaneous tissue disorders Psoriasis	3.5% 4/113 • From Baseline (enrollment) until Month 12 Same event may occur as both non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. SAF included all participants who received at least one dose (including partial dose) of study medication independently of inclusion/exclusion criteria.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER